Gankyrin inhibitors are a group of compounds that can reduce the function of gankyrin, either directly or indirectly, through their actions on various biochemical and cellular pathways. Gankyrin, an oncoprotein, is involved in several key cellular processes including cell cycle progression, cell proliferation, and apoptosis. Consequently, it influences numerous signaling pathways such as the RAF/MEK/ERK pathway, PI3K/AKT/mTOR pathway, SRC/FAK pathway, and EGFR/RAS/RAF/MEK/ERK pathway among others. The inhibitors of gankyrin range from kinase inhibitors, mTOR inhibitors to cyclin-dependent kinase inhibitors, each with a specific target and mode of action that ultimately results in the modulation of gankyrin's activity. Kinase inhibitors, such as sorafenib, dasatinib, gefitinib, selumetinib, trametinib, lapatinib, sunitinib, nilotinib, and vemurafenib, function by inhibiting specific kinases involved in the various signaling pathways that gankyrin supports. For instance, sorafenib, a RAF kinase inhibitor, can attenuate the RAF/MEK/ERK pathway, leading to a decrease in gankyrin's enhancing effect on cell proliferation and survival. Similarly, dasatinib, a BCR-ABL and SRC family kinase inhibitor, can disrupt the SRC/FAK pathway, reducing gankyrin's effect on cell migration and invasion.
mTOR inhibitors, such as everolimus and rapamycin, function by inhibiting mTOR, a key component of the PI3K/AKT/mTOR pathway. By disrupting this pathway, these inhibitors can reduce gankyrin's promoting effect on cell proliferation and survival. Palbociclib, on the other hand, is a selective inhibitor of cyclin-dependent kinases 4 and 6. Its action on these kinases disrupts the cell cycle, a process that gankyrin is known to promote, leading to a decrease in gankyrin's impact on cell proliferation. In summary, gankyrin inhibitors are a diverse group of compounds that can modulate the activity of gankyrin by influencing various biochemical and cellular pathways that gankyrin supports. These inhibitors offer a potential means of controlling gankyrin's role in cell proliferation, survival, and migration.
SEE ALSO...
Items 11 to 12 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Palbociclib | 571190-30-2 | sc-507366 | 50 mg | $315.00 | ||
Palbociclib is a selective inhibitor of cyclin-dependent kinases 4 and 6. By inhibiting CDK4/6, it can disrupt the cell cycle, which gankyrin is known to promote, leading to a decrease in gankyrin's impact on cell proliferation. | ||||||
Vemurafenib | 918504-65-1 | sc-364643 sc-364643A | 10 mg 50 mg | $115.00 $415.00 | 11 | |
Vemurafenib is a BRAF inhibitor. By inhibiting BRAF, it can disrupt the RAS/RAF/MEK/ERK pathway, which gankyrin is known to support. This can lead to a decrease in gankyrin's enhancing effect on cell proliferation and survival. | ||||||